NextCure, Inc. Common Stock (NXTC) Stock Price

NXTCStock

$6.24−28.28%52W

Market Cap$28.56M

P/E—

PEG Ratio—

Div yield—

Beta1.27

NXTC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-61.04%

Price vs S&P 500 (4W)15.61%

VGM Score65.55

Book Value / Share (Quarterly)$2.99

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-9.09

Price vs S&P 500 (YTD)-67.95%

Net Profit Margin (TTM)-65.22%

EPS (TTM)$-10.27

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-10.27

EPS (Annual)$-2.00

ROI (Annual)-85.53%

Net Profit Margin (5Y Avg)-825.97%

Cash / Share (Quarterly)$4.94

ROA (Last FY)-69.26%

EBITD / Share (TTM)$-9.88

ROE (5Y Avg)-45.43%

Operating Margin (TTM)-82.06%

Cash Flow / Share (Annual)$-14.15

P/B Ratio2.35x

P/B Ratio (Quarterly)0.54x

Net Income / Employee (Annual)$-1,400,000

EV / Revenue (TTM)0.49x

ROA (TTM)-113.70%

EPS Incl Extra (Annual)$-2.00

Current Ratio (Annual)4.14x

Quick Ratio (Quarterly)3.13x

3-Month Avg Trading Volume1.54M

52-Week Price Return-28.28%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.54

P/S Ratio (Annual)1.28x

Asset Turnover (Annual)0.07x

52-Week High$15.74

Operating Margin (5Y Avg)-865.37%

EPS Excl Extra (Annual)$-2.00

CapEx CAGR (5Y)-32.45%

Tangible BV CAGR (5Y)60.79%

26-Week Price Return-51.14%

Quick Ratio (Annual)3.96x

13-Week Price Return4.17%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.47x

Enterprise Value$13.30M

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-1.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-163.54%

Cash / Share (Annual)$11.93

3-Month Return Std Dev139.86%

Net Income / Employee (TTM)$-1,068,700

ROE (Last FY)-85.53%

EPS Basic Excl Extra (Annual)$-2.00

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.27

ROI (TTM)-175.46%

P/S Ratio (TTM)1.04x

Pretax Margin (5Y Avg)-825.97%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.03

Price vs S&P 500 (52W)-43.81%

Year-to-Date Return-56.03%

5-Day Price Return-6.02%

EPS Normalized (Annual)$-2.00

ROA (5Y Avg)-39.88%

Net Profit Margin (Annual)-163.54%

Month-to-Date Return24.55%

Cash Flow / Share (TTM)$-2.22

EBITD / Share (Annual)$-2.04

Operating Margin (Annual)-184.23%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-45.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.27

P/TBV (Quarterly)0.28x

P/B Ratio (Annual)1.42x

Pretax Margin (TTM)-65.22%

Book Value / Share (Annual)$9.97

Price vs S&P 500 (13W)1.49%

Beta1.27x

P/FCF (Annual)5.79x

Revenue / Share (TTM)$0.00

ROE (TTM)-175.46%

52-Week Low$1.55

vGradeB

mGradeC

vgmGradeB

NXTC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.92	-$1.85	+3.85%(+$0.07)
Q1 2026	May 7, 2026	-$2.03	-$1.87	+7.88%(+$0.16)
Q4 2025	Mar 5, 2026	-$2.29	-$0.81	+64.63%(+$1.48)
Q3 2025	Nov 5, 2025	-$3.98	-$3.22	+19.16%(+$0.76)
Q2 2025	Aug 7, 2025	-$4.62	-$11.29	-144.64%(-$6.67)

NXTC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.22

4.13

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NXTCNextCure, Inc. Common Stock	B	—	C	1.0x	—	—	—	$6.24
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About NextCure, Inc. Common Stock

NextCure is a clinical-stage biopharmaceutical company developing immunomedicines to restore immune function in cancer and immune-related diseases. Its lead candidate, NC410, a LAIR-2 fusion protein, demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, while LNCB74, an antibody-drug conjugate targeting B7-H4, is also in clinical development. The company is seeking strategic partners for additional clinical programs including NC525 and NC318, as well as preclinical candidates in chronic bone diseases and neurological indications.

NXTC Insider Transactions

SellAug 10, 2026
SIMCERE ZAIMING, INC
Unknown
Shares: 30,000Value: $184,800
BuyJul 31, 2026
ADAR1 CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 329,153Value: $1.60M
BuyJul 29, 2026
ADAR1 CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security
Shares: 17,608Value: $87,713

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

UGUnited-Guardian, Inc.Cosmetics & Toiletries
AVDAmerican Vanguard CorporationAgricultural Chemicals
ALGSAligos Therapeutics, Inc. Common StockBiological Products
MGXMetagenomi Therapeutics, Inc. Common StockBiological Products
EVAXEvaxion A/S American Depositary ShareBiological Products
BKHABlack Hawk Acquisition Corporation Class A Ordinary SharesBiological Products
SCLXScilex Holding Company Common StockBiological Products
ESLAEstrella Immunopharma, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$1.55

High$15.74